Val Brunton
Chair of Cancer Therapeutics
- Cancer Research UK Edinburgh Centre
- MRC Institute of Genetics & Cancer
Contact details
- Tel: +44 (0)131 651 8690
- Email: v.brunton@ed.ac.uk
Address
- Street
-
Cancer Research UK Edinburgh Centre
MRC Institute of Genetics & Cancer
The University of Edinburgh
Western General Hospital
Crewe Road South - City
- Edinburgh
- Post code
- EH4 2XR
Background
Prof Brunton gained her BSc Hons in Pharmacology from the University of Aberdeen. After being awarded her PhD in 1990 she moved to the Department of Medical Oncology at the University of Glasgow with Prof Paul Workman and spent three years working on the preclinical development of EGF receptor tyrosine kinase inhibitors. She then moved to the Beatson Institute for Cancer Research as a post-doc with Prof Margaret Frame where she worked on the role of the non-receptor tyrosine kinases Src and FAK in tumour cell progression. She has been involved in both the preclinical and clinical development of FAK and Src inhibitors, and continues to work on the development of these and other targeted agents since taking up her position as head of the Cancer Therapeutics group at the ECRC in 2008. She was appointed as chair of Cancer Therapeutics at the University of Edinburgh in 2013.
-
Stretching the Bisalkyne Raman Spectral Palette Reveals a New Electrophilic Covalent Motif
In:
Chemistry - A European Journal
DOI: https://doi.org/10.1002/chem.202300953
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Kindlin-1 regulates IL-6 secretion and modulates the immune environment in breast cancer models
In:
eLIFE, vol. 12
DOI: https://doi.org/10.7554/eLife.85739
Research output: Contribution to Journal › Article (Published) -
SKOR1 mediates FER kinase-dependent invasive growth of breast cancer cells
In:
Journal of Cell Science, vol. 136
DOI: https://doi.org/10.1242/jcs.260243
Research output: Contribution to Journal › Article (Published) -
CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer
In:
Nature Communications, vol. 14
DOI: https://doi.org/10.1038/s41467-023-35793-w
Research output: Contribution to Journal › Article (E-pub ahead of print) -
11β-HSD1 inhibition does not affect murine tumour angiogenesis but may exert a selective effect on tumour growth by modulating inflammation and fibrosis
In:
PLoS ONE, vol. 18, pp. e0255709
DOI: https://doi.org/10.1371/journal.pone.0255709
Research output: Contribution to Journal › Article (Published)